
    
      This is a Phase 3, Pragmatic, Multicentric Randomized Controled Trial of efficacy to test the
      effect of either Chloroquine or Hydroxychloroquine for 5 days in the recomended dose
      standardized by brazilian Ministry of Health.

      Patients were randomized (1:1) using stratified randomization by hospital and severity at the
      moment of randomization (stipulated by use of mechanical ventilation or not) into two arms:
      Intervention and Control. Intervention group recieved a loading dose of 900mg of Chloroquine
      or 800mg of Hydroxycloroquine in the first day, followed by 450mg of chloroquine of 400mg of
      hydroxychloroquine. Primary and secondary outcomes were evaluated on the 5th, 7th, 10th,
      14th, 28th day after randomization.

      Although the outcomes presented in the latest version were updated late on
      ClinicalTrials.org, on October 23, 2020, these outcomes were already present in the trial
      protocol approved by the Brazilian National Commission for Ethics in Research on April 8,
      2020 (approval number: 3960331) and amending the protocol, approved by the same National
      Commission on May 25, 2020 (approval number: 4044848)
    
  